{ "tag": [ "compiled" ], "id": "ocds-h6vhtk-02a974-2021-10-11T14:33:44+01:00", "date": "2021-10-11T14:33:44+01:00", "ocid": "ocds-h6vhtk-02a974", "initiationType": "tender", "tender": { "id": "CM/PHV/14/5433", "legalBasis": { "id": "32014L0024", "scheme": "CELEX" }, "title": "Contract for the supply of live attenuated intranasal influenza vaccine", "status": "complete", "classification": { "scheme": "CPV", "id": "33651660", "description": "Influenza vaccines" }, "mainProcurementCategory": "goods", "description": "Provision for a contract for the supply of live attenuated intranasal influenza vaccine", "lots": [ { "id": "1", "description": "The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine.", "awardCriteria": { "criteria": [ { "name": "Cost", "type": "cost", "description": "0" } ] }, "hasOptions": false, "status": "cancelled", "contractPeriod": { "startDate": "2018-08-01T00:00:00+01:00", "endDate": "2022-07-31T23:59:59+01:00" } } ], "items": [ { "id": "1", "deliveryAddresses": [ { "region": "UK" }, { "region": "UK" } ], "deliveryLocation": { "description": "Bedford, UK" }, "relatedLot": "1" } ], "procurementMethod": "limited", "procurementMethodDetails": "Award procedure without prior publication of a call for competition", "coveredBy": [ "GPA" ], "procurementMethodRationaleClassifications": [ { "scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL", "id": "D_TECHNICAL", "description": "The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons" } ], "procurementMethodRationale": "There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015.", "amendments": [ { "id": "1", "unstructuredChanges": [ { "oldValue": { "date": "2021-03-20" }, "newValue": { "date": "2021-03-21" }, "where": { "section": "V.2.1.1", "label": "Contract conclusion date" } }, { "oldValue": { "text": "AstraZeneca 1 Francis Crick Avenue, Cambridge, United Kingdom, LCB2 0AA Registration number: 3674842" }, "newValue": { "text": "AstraZeneca UK Limited 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA Registration number: 03674842" }, "where": { "section": "V.2.3.1", "label": "Address of the Contractor" } }, { "oldValue": { "text": "There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015." }, "newValue": { "text": "DHSC is procuring these vaccines on the recommendation of the JCVI that this type of vaccine should be offered . There is only one supplier of this type of vaccine with the applicable Marketing Authorisation in the UK and, due to the functions of the vaccine, there is no reasonable alternative or substitute currently licenced for use in the UK. Competition is therefore absent for technical reasons and the use of the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) of the Public Contract Regulations 2015 (as amended)." }, "where": { "section": "IV.1.1.1", "label": "Explanation" } }, { "oldValue": { "text": "CM/PHV/14/5433_1" }, "newValue": { "text": "CM/PHV/14/5433" }, "where": { "section": "II.1.1.2", "label": "Reference number" } } ] } ] }, "awards": [ { "id": "008707-2021-1", "relatedLots": [ "1" ], "status": "active", "suppliers": [ { "id": "GB-FTS-13940", "name": "AstraZeneca" } ] }, { "id": "025357-2021-CM/PHV/14/5433-1", "relatedLots": [ "1" ], "status": "active", "suppliers": [ { "id": "GB-FTS-31289", "name": "AstraZeneca" } ] } ], "parties": [ { "id": "GB-FTS-43", "name": "Department of Health and Social Care", "identifier": { "legalName": "Department of Health and Social Care" }, "address": { "streetAddress": "39 Victoria Street", "locality": "London", "region": "UKI32", "postalCode": "SW1H 0EU", "countryName": "United Kingdom" }, "contactPoint": { "email": "chantal.jockel@dhsc.gov.uk" }, "roles": [ "buyer" ], "details": { "url": "https://www.gov.uk/government/organisations/department-of-health-and-social-care", "buyerProfile": "https://www.gov.uk/government/organisations/department-of-health-and-social-care", "classifications": [ { "scheme": "TED_CA_TYPE", "id": "MINISTRY", "description": "Ministry or any other national or federal authority, including their regional or local subdivisions" }, { "scheme": "COFOG", "id": "07", "description": "Health" } ] } }, { "id": "GB-FTS-13940", "name": "AstraZeneca", "identifier": { "legalName": "AstraZeneca", "id": "3674842" }, "address": { "streetAddress": "1 Francis Crick Avenue", "locality": "Cambridge", "region": "UKH1", "postalCode": "LCB2 0AA", "countryName": "United Kingdom" }, "roles": [ "supplier" ], "details": { "scale": "large" } }, { "id": "GB-FTS-497", "name": "The High Court", "identifier": { "legalName": "The High Court" }, "address": { "streetAddress": "Strand", "locality": "London", "postalCode": "WC2A 2LL", "countryName": "United Kingdom" }, "contactPoint": { "email": "generaloffice@administrativecourtoffice.justice.gov.uk" }, "roles": [ "reviewBody" ], "details": { "url": "https://www.gov.uk/courts-tribunals" } }, { "id": "GB-FTS-31289", "name": "AstraZeneca", "identifier": { "legalName": "AstraZeneca", "id": "03674842" }, "address": { "streetAddress": "1 Francis Crick Avenue", "locality": "Cambridge", "region": "UKH1", "postalCode": "LCB2 0AA", "countryName": "United Kingdom" }, "roles": [ "supplier" ], "details": { "url": "http://www.astrazeneca.co.uk", "scale": "large" } } ], "buyer": { "id": "GB-FTS-43", "name": "Department of Health and Social Care" }, "contracts": [ { "id": "008707-2021-1", "awardID": "008707-2021-1", "status": "active", "value": { "amount": 1, "currency": "GBP" }, "dateSigned": "2021-03-20T00:00:00Z" }, { "id": "025357-2021-CM/PHV/14/5433-1", "awardID": "025357-2021-CM/PHV/14/5433-1", "status": "active", "value": { "amount": 1, "currency": "GBP" }, "dateSigned": "2018-02-09T00:00:00Z", "period": { "startDate": "2018-08-01T00:00:00+01:00", "endDate": "2022-07-31T23:59:59+01:00" }, "items": [ { "id": "1", "classification": { "scheme": "CPV", "id": "33651660", "description": "Influenza vaccines" }, "deliveryAddresses": [ { "region": "UK" } ], "deliveryLocation": { "description": "Bedford, UK" }, "relatedLot": "1" } ], "amendments": [ { "id": "2", "description": "The provision of additional doses of live attenuated intranasal influenza vaccine, to be used to support the annual seasonal influenza vaccination programme in the UK. The additional volume requirement is 37,160 doses of vaccine.", "rationale": "Need for additional works, services or supplies by the original contractor/concessionaire: The additional doses of LAIV are necessary for the Government's children's flu programme; AstraZeneca have exclusive rights to manufacture and supply a LAIV product (Fluenz Tetra) and are the only supplier in the UK of a LAIV product with marketing authorisation which means DHSC cannot engage another supplier to provide the additional doses without significant inconvenience" } ] } ], "bids": { "statistics": [ { "id": "1", "measure": "bids", "relatedLot": "1", "value": 1 } ] }, "language": "en", "description": "Value -- this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interest of the supplier." }